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Synonymous mutations change the sequence of
a gene without directly altering the sequence of
the encoded protein. Here, we present evidence
that these ‘‘silent’’ mutations frequently contribute
to human cancer. Selection on synonymous
mutations in oncogenes is cancer-type specific,
and although the functional consequences of
cancer-associated synonymous mutations may be
diverse, they recurrently alter exonic motifs that
regulate splicing and are associated with changes
in oncogene splicing in tumors. The p53 tumor sup-
pressor (TP53) also has recurrent synonymous
mutations, but, in contrast to those in oncogenes,
these are adjacent to splice sites and inactivate
them. We estimate that between one in two
and one in five silent mutations in oncogenes
have been selected, equating to 6%– 8% of all
selected single-nucleotide changes in these genes.
In addition, our analyses suggest that dosage-sen-
sitive oncogenes have selected mutations in their
30 UTRs.
INTRODUCTION
Cancer genomes contain not only cancer-causing ‘‘driver’’
mutations, but also many additional accumulated ‘‘passenger’’
mutations that do not contribute directly to the tumor
phenotype (Stratton et al., 2009). A key challenge in can-
cer research is to distinguish the consequential driver muta-
tions from the inconsequential passenger mutations. Given
the recent explosion in the number of sequenced cancer
genomes, this challenge is particularly pressing (Vogelstein
et al., 2013).
Decades of research have revealed that somatic mutations
affect cancer genes through diverse molecular mechanisms.
For example, oncogenes can be activated by amino acid-
altering missense mutations, by amplifications, and by translo-
cations. Tumor suppressor genes, in contrast, are inactivated1324 Cell 156, 1324–1335, March 13, 2014 ª2014 Elsevier Inc.by local or large-scale deletions and loss of heterozygosity,
by the introduction of premature stop codons or frameshifts,
and bymutations in introns that inactivate pre-mRNA splice sites
(Vogelstein et al., 2013). In the large-scale analyses of cancer
genomes performed to date, it is these previously established
common mechanisms that have been considered (Stratton
et al., 2009; Vogelstein et al., 2013).
However, the extent of sequence data that are now available
for tumor samples should also allow the identification of addi-
tional classes of common oncogenic mutations. If such new
types of driver mutations exist and they are not considered,
then our ability both to interpret cancer genomes in general
and to understand the causes of oncogenesis in individual
patients would be compromised.
The universal genetic code uses 61 codons to encode 20
amino acids. The redundancy in this code means that many
nucleotide changes can be made in the sequence of a gene
without affecting the sequence of the encoded protein. Synon-
ymous or ‘‘silent’’ positions in a gene’s sequence can be
used to encode additional information that affects prop-
erties such as the speed or accuracy with which an mRNA is
translated (Drummond and Wilke, 2008), how an mRNA is
folded (Goodman et al., 2013) or spliced (Parmley et al.,
2006), or, through translational pausing, how a protein folds
(Zhang et al., 2009; Zhou et al., 2013). These and other
mechanisms mean that changes in a gene’s sequence that
are silent with respect to protein sequence are not always
silent with respect to function (Gingold and Pilpel, 2011).
Indeed, there is growing evidence that natural selection acts
widely on synonymous sites (Drummond and Wilke, 2008;
Supek et al., 2010).
Based on their evolutionary importance, individual examples
(Gartner et al., 2013; Griseri et al., 2011; Ma et al., 2009; Schutz
et al., 2013), and their potential role in other human diseases
(Sauna and Kimchi-Sarfaty, 2011), we hypothesized that synon-
ymous mutations might also frequently contribute to cancer.
Here, in an analysis of >3,000 cancer exomes and >300 cancer
genomes, we present robust statistical evidence that this is
indeed the case: that synonymous mutations must frequently
contribute to cancer. These silent mutations in exons may act
through diverse molecular mechanisms, and they are often
associated with changes in splicing.
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C D Figure 1. Classes of Cancer Genes and
Their Corresponding Matched Gene Sets
(A) Cancer Gene Census, subdivided by mech-
anism of (in)activation. ‘‘Recurrently mutated
genes,’’ are from 34 cancer genome papers.
(B) Principal components analysis of regional so-
matic mutation rates in cancer or known correlates
thereof.
(C and D) Cumulative histograms of distributions of
genomic variables in the recurrently mutated on-
cogenes (C) or tumor suppressors (D) against
a matched set and all other genes (5th–95th
percentile shown). ‘‘D+/’’ are Kolmogorov-Smir-
nov statistics quantifying if a variable is stochas-
tically smaller (D+) or larger (D) in the cancer
genes; one-tailed p value is given below.
See also Figure S7 and Tables S1 and S2.RESULTS
Employing Matched Gene Sets to Control for Regional
Variation in Mutation Frequencies in Cancer Exome
Data
Previous studies have distinguished cancer-causing driver
mutations from background passenger mutations by comparing
the frequency of protein-coding changes to the frequency of
synonymous mutations in the same genes (Ding et al., 2008; Pei-
fer et al., 2012). However, a search for selection acting on synon-
ymousmutations necessarily has to rely on a different approach.
We used the Cancer Gene Census (CGC) (Futreal et al., 2004;
Santarius et al., 2010) to define three sets of known oncogenes
according to their mechanism of activation and a set of known
tumor suppressor genes (Figure 1A). Additionally, we collected
a larger set of cancer genes consisting of those reported as
recurrently mutated in 34 recent cancer genome sequencing
studies (Table S1 available online). For each of these gene lists,
we ran an optimization procedure to create a set of non-cancer
genes matching the cancer gene list in the distribution of their
regional point mutation rates at 200 kb and 1 Mb resolution
and also for a set of features implicated in mutation rate variation
(the heterochromatin-associated nucleosome modification
H3K9me3, replication timing, base composition [GC3 content]
and mRNA expression levels) across tissues (Hodgkinson
et al., 2012; Pleasance et al., 2010; Schuster-Bo¨ckler and Leh-
ner, 2012; Woo and Li, 2012); the complete list of features is
given in Table S2, and a principal components plot summarizingCell 156, 1324–1335the relationships between these features
is shown in Figure 1B. For instance, the
39 recurrently mutated oncogenes from
the CGC are situated in genomic regions
with significantly higher mutation rates,
higher levels of heterochromatin, and
later replication times (Figure 1C), and
they are also more highly expressed
than the general gene set (Figure 1C).
The matched set here consists of 1,517
genes that closely follow the 39 onco-
genes in all of these features. In contrast,the 38 recurrently mutated tumor suppressor genes lie in signif-
icantly lessmutable, less heterochromatic, and earlier replicating
regions of the genome (Figure 1D); the corresponding matched
set again compensates for these differences (Figure 1D).
Oncogenes, but Not Tumor Suppressor Genes, Contain
an Excess of Somatic Synonymous Mutations in Human
Tumors
We next compiled a data set of 292,405 missense and 123,193
synonymous somatic mutations identified in the exomes of
3,851 cancer samples. These include tumors from 11 different
tissues with more than 200 samples each (Table S2). As ex-
pected, missense mutations are enriched in previously reported
oncogenes and tumor suppressor genes (Figure 2A). Strikingly,
however, oncogenes known to be activated by missense muta-
tions are also enriched for synonymous mutations in the 3,851
cancer exomes (Figure 2A), with a 23%–30% excess of synony-
mous mutations compared to genes in their matched control set
(p = 3 3 106 and p = 7 3 1010; Figure 2A). In contrast, this is
not the case for tumor suppressor genes, which actually show
a slight depletion for synonymous mutations (Figure 2A).
To further test for any additional unaccounted source of varia-
tion in mutation rates, we also quantified the enrichment of mu-
tations in introns. In all cases, the enrichments ofmutations in the
introns of oncogenes and tumor suppressors compared to the
matched gene sets were close to 1 (Figure 2D). Importantly,
the intronic mutation rates of the oncogenes were not elevated
compared to the matched sets when assessed both in the set, March 13, 2014 ª2014 Elsevier Inc. 1325
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Figure 2. Enrichment of Synonymous Mutations in Oncogenes, but Not in Tumor Suppressor Genes, Is Cancer-Type Specific and Is Not due
to Co-Occurrence with Nonsynonymous Mutations
(A) Mutation enrichments in cancer genes compared to matched sets.
(B and C) Distribution of synonymous enrichments for non-cancer genes in 164 Gene Ontology categories (B) or for oncogenes after 100 bootstrap samples (C).
p value by Z-test (one tailed).
(D) Mutation enrichment across 395 cancer whole-genome sequences.
(E and F) Synonymous mutation enrichments of cancer genes classes evaluated independently of the matched sets: a comparison to neighboring genes (E) and
the Invex randomization test (F). Error bars are 95% CI.
(G) Synonymous enrichments for cancer genes determined separately for tissues. Exome counts shown in pie chart. p values are by Z-test.
(H and I) Synonymous enrichments for the complete and for the tissue-specific cancer gene sets (Table S5), for oncogenes (H) and tumor suppressors (I). p values
are by paired t test (one tailed, for tissue specific > general enrichment). Blood (BLO) or brain (BRA) tumors did not register synonymous mutations in the tissue-
specific tumor suppressors and oncogenes, respectively, and are thus not shown.
(J) Co-occurrence of missense and synonymous mutations in the same genes in the same tumor samples. Gene counts in parentheses or ranges of counts for
tissue-specific sets.
(K) Synonymous enrichments after removing mutations with another nonsynonymous mutation in the same gene (or on the same chromosome) in the same
cancer sample. Error bars are 95% CI.
See also Figures S1, S2, and S6 and Tables S2, S3, and S4.
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of 176 whole-genome sequences used in the matching proce-
dure (1.033 and 1.043; Figure 2D) and in an independent set
of 219 genomes (1.053 and 1.043; Figure 2D). Moreover, the
oncogenes’ UTRs were not enriched with mutations compared
to the matched sets (0.963 and 0.973; Figure 2D). This is in
contrast to the synonymous mutation frequency, which is simi-
larly elevated in the set of whole-genome sequences (1.273
and 1.323; Figure 2D). Thus, increases in local mutation rates
cannot account for the elevated synonymous mutation rates in
oncogenes.
The mutation spectra of synonymous mutations in oncogenes
closely reflect those of their matched sets (Table S3), meaning
that differences in sequence composition do not underlie the
observed increases in synonymous mutation rates. Moreover,
oncogenes are highly enriched for synonymous mutations
compared to other gene functional categories (p = 0.014; histo-
gram in Figure 2B). Finally, bootstrapping to remove bias (Fig-
ure S1) resulted in a slightly higher estimate of synonymous
enrichment of the oncogenes (1.343; Figure 2C) as well as an
estimate of a confidence interval (CI) that accounts for the vari-
ance of the matching algorithm (95% CI: 1.18–1.49).
Considering Mutations in Introns and in Neighboring
GenesConfirms the Excess of SynonymousMutations in
Oncogenes
We validated our findings using two additional methodologies
that are orthogonal to the matched-sets approach. First, we
compared the synonymous mutation rates in oncogenes to
those in neighboring genes in the genome. Whereas tumor sup-
pressor genes and amplification- or translocation-activated
oncogenes show no evidence of an elevated frequency of syn-
onymous mutation compared to their neighbors (Figure 2E),
missense-activated oncogenes have an excess of synonymous
mutations (1.203 and 1.373 for the two gene sets; Figure 2E),
strikingly similar to that determined using the mutation-rate
matched gene sets.
Second, we employed the Invex randomization test (Hodis
et al., 2012) that simulates mutations in the coding sequence
by sampling from the intronic and UTR mutations of the same
gene. This test stringently controls for variations in mutation rates
andspectra. The Invex test estimates 1.203 and1.253 increased
synonymous mutation rates in oncogenes (Figure 2F). We also
compared the rates of missense mutations determined using
this method to those determined using the Invex test and again
found a striking agreement (R2 = 0.991 across cancer gene clas-
ses; Figure S1), further validating the matched-sets approach.
Co-Occurring Mutations Do Not Account for the Excess
of Synonymous Mutations in Oncogenes
One possible explanation for the enrichment of synonymous
mutations in oncogenes is that they represent the phenomenon
of clustered mutations or ‘‘mutation showers’’ (Roberts et al.,
2012;Wang et al., 2007). For example, if amutation process gen-
eratesmultiple mutations in a gene, then functionally neutral syn-
onymous mutations could be enriched in oncogenes because
of ‘‘hitchhiking’’ with missense mutations that are positively
selected. However, this model cannot explain the enrichment
of synonymous mutations in oncogenes, because samplesharboring missense mutations in a particular oncogene are un-
likely to also harbor synonymous mutations in the same gene
(odds ratio [OR] = 0.53, p = 33 106; Figure 2J). This avoidance
is even stronger in the oncogenes most frequently mutated in a
particular tissue (OR = 0.29, p = 4 3 108; Figure 2J). Moreover,
such strong avoidance is not observed for tumor suppressor
genes, where we see no enrichment for synonymous mutations
(Figure 2J). Consistently, if we filter out all synonymous muta-
tions in genes already harboring a nonsynonymous mutation in
the same sample, the synonymous enrichment of oncogenes is
retained (1.223, p = 4 3 105; Figure 2K), as is also the case
when removing all synonymous mutations occurring on chromo-
somes containing any additional nonsynonymous mutations in
any gene (Figure 2K; p = 0.003).
Synonymous Mutations Are Selected for in a Tissue-
Specific Manner
The frequency of missense mutation in individual oncogenes is
not evenly distributed across tissues. For example, the onco-
gene BRAF is frequently mutated in melanoma, whereas KRAS
is frequently mutated in colorectal cancer. We quantified the fre-
quencies of synonymous mutations separately for cancers of
different tissues and observed a consistent trend of enrichment
in the oncogenes and depletion in the tumor suppressors across
the 11 tissues (Figure 2G). The enrichment of synonymous muta-
tions in oncogenes is lower in tissues with a high mutational load
(1.10–1.263 in lung, melanoma, or head and neck cancers; Fig-
ure 2H) and stronger in tissues with a low mutational load (1.44–
1.593 in leukemia, breast, and ovarian cancer; Figure 2H),
consistent with a lower signal-to-noise ratio in highly mutated
genomes. When considering individual tissues, synonymous
mutations are enriched in the same tissue-specific oncogenes
(list in Table S4) as missense mutations (Figure 2H; median syn-
onymous enrichment over tissues = 1.983 compared to me-
dian = 1.293 for the complete oncogene set; p = 1.3 3 103).
This is not the case for tumor suppressor genes (Figure 2I; me-
dian enrichment = 0.723). Again, this is not due to synonymous
and missense mutations co-occurring in the same genes in the
same sample (Figure S2; median enrichment = 1.843; p = 5 3
103). Tissue-specific oncogenes do not exhibit different
dinucleotide compositions in their exons (Figure S2), making it
unlikely that tissue-specific mutational processes underlie this
enrichment. Thus, in a particular tissue, synonymous and
missense mutations tend to target the same oncogenes.
Cancer-Associated Synonymous Mutations
Preferentially Target Conserved Sites and Particular
Regions of Oncogenes
Themolecularmechanismsbywhich synonymousmutations can
affect gene activity are diverse (Sauna andKimchi-Sarfaty, 2011).
However, we reasoned that some molecular mechanisms might
be more common than others, and so we identified a group of
16 known oncogenes with a high (>1.53) enrichment with synon-
ymousmutations for further analysis of putativemolecular effects
(Figures 3A–3C). Within this set, 11 genes are also individually
significantly enriched with synonymous mutations (false discov-
ery rate [FDR] < 9%). These are the receptor tyrosine kinases
PDGFRA, EGFR, KDR (VEGFR2), and NTRK1, the receptorsCell 156, 1324–1335, March 13, 2014 ª2014 Elsevier Inc. 1327
AB
C D
E F G
H
I
Figure 3. Oncogenes Most Targeted by
Synonymous Mutations and Mutation
Clustering
(A and B) Enrichment of individual oncogenes
compared to a matched set of 200 non-cancer
genes. Error bars are 95% CI. Significance by
Z-test of log enrichment (one tailed). Bars darker
for individually significant genes at p < 0.025
(%9% FDR).
(C) The 16 oncogenes with >1.53 enrichment
examined in the following panels and Figure 4.
(D) Enrichment with intronic and UTR mutations in
the significant oncogenes.GATA1 not shown (only
one mutation, enrichment = 0.173). Error bars are
95% CI for the noncoding enrichment. p value by
paired t test, one tailed.
(E–G) Clustering of synonymous and missense
mutations; p values are by Fisher’s exact test
(one-tailed).
(H and I) Prominent examples of clusters of three
or more recurrent mutations, only synonymous (I),
or also missense (H). Amino acid changes given
next to the mutated codon, along with the TCGA
or Cosmic sample ID.
See also Figures S1, S3, and S4 and Tables S5
and S6.IL7R and TSHR, the structural protein ELN, the cytoplasmic
kinases JAK3 and ITK, and the transcription factors GATA1
and RUNX1T1. In addition to this set, the oncogenes ALK
and NOTCH2 are also individually significant, at 1.473 and
1.463 enrichment. The increased synonymous mutation rates
in these genes are not associated with a comparable increase
in intronic and UTR mutation rates (Figure 3D; p = 5.7 3 104),
ruling out a role for an elevated local mutation rate. In addition
to the above oncogenes, a tissue-specific synonymous enrich-
ment could be detected for other genes, most consistently for
the JAK2 and RET kinases and for the SF3B1 splicing factor
(at least two tissues at FDR% 10%; list in Table S5).
First, we considered whether cancer-associated synonymous
mutations preferentially target evolutionarily conserved synony-
mous sites (Lin et al., 2011) and found that this was indeed the
case (Figure S1). This enrichment is not observed for tumor sup-
pressors (Figure S1) and is confirmed using an alternative mea-
sure of sequence constraint (Pollard et al., 2010) (Figure S1).1328 Cell 156, 1324–1335, March 13, 2014 ª2014 Elsevier Inc.Missense mutations are known to clus-
ter together in the linear sequence of on-
cogenes, reflecting the arrangement of
functionally important sites in a protein.
Synonymous mutations also significantly
cluster in known oncogenes (Figure 3E)
and evenmore so in the top-16 oncogene
set, where a synonymous mutation is
more likely to occur within five codons
of another synonymous-mutated site
(OR = 1.74, p = 106; Figure 3E), an effect
size similar to the missense-missense
clustering in the same genes (OR = 1.92;
Figure 3F). Again, such an association isabsent in tumor suppressors for synonymous mutations (OR =
0.94), but not, as expected, for missense mutations (OR =
2.29). Interestingly, we found that the synonymous mutations
in the 16-oncogene set also cluster significantly with the
missense mutations, albeit to a lesser extent (OR = 1.24; Fig-
ure 3G). The clustering of the synonymous mutations is not
due to hitchhiking effects, because it is not altered after
removing cases where the gene also contained a nonsynony-
mous mutation in the same sample (OR = 1.71, p = 2 3 105;
striped bars in Figure 3E). Individual examples of clustered mu-
tations are shown in Figure 4I and 4H, with the complete set in
all highly enriched oncogenes in Figure S3.
Cancer-Associated Synonymous Mutations Do Not
Frequently Increase CodonOptimality ormRNA Stability
or Inactivate Exonic miRNA Target Sites
Next, we considered the possibility that cancer-associated
synonymous mutations function by increasing the use of more
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Figure 4. Cancer-Associated Synonymous Mutations Create Exonic Splicing Enhancers and Destroy Exonic Splicing Silencers
(A) Enrichment of synonymous mutations near splice sites (SS). Odds ratios and p values by c2 test shown above.
(B–D) Enrichments of synonymous mutations within 30 nt of SS that lead to exonic splicing silencer (ESS) or exonic splicing enhancer (ESE) gain or loss events. y
axes display odds ratios versus different baselines, counting those mutations leading to a gain/loss of an ESE/S; p values by c2 test. Error bars are 95%CI of the
odds ratio.
(E) Cumulative histograms of SS agreement to consensus motif for exons with above- versus below-median densities of synonymous mutations. D+ is the
Kolmogorov-Smirnov (K-S) statistic. p value is from the two K-S tests combined using Fisher’s method. PWM, position weight matrix.
(F and G) Sequence contexts around synonymous mutations leading to ESE gains (F) or to ESS losses (G) clustered. Similar known motifs of ESE/ESS binding
proteins shown for comparison. Bar charts show number of sequences above binding threshold for splicing factors (F) or in searches for similar motifs among
RNA binding proteins (G).
(A)–(G) show data for the 16 oncogenes most enriched with synonymous mutations.optimal codons, thereby enhancing the efficiency or accuracy of
oncogene translation (Drummond and Wilke, 2008). However,
we found no evidence that cancer-associated synonymous
mutations, considered as a set, increase codon optimality (Fig-
ure S4), as judged using the genomic tRNA gene copy number
(Table S6). We also considered the potential influence of synon-
ymous mutations on mRNA secondary structure, which is also
known to affect translation efficiency (Goodman et al., 2013).
However, the computationally predicted mRNA structures
(Markham and Zuker, 2008) in 50 and 100 nt windows overlap-
ping synonymously mutated sites did not show a general ten-
dency toward more open structures when mutated (Figure S4).
We also considered that synonymous mutations might affect
oncogene expression by abolishing exonic microRNA (miRNA)
target sites (Brest et al., 2011) but again found no evidence for
this, considering either all sites or only those with evidence
of evolutionary conservation at synonymous sites (Figure S4).
Therefore, effects on codon optimality, mRNA folding, and
miRNA targeting do not seem to be common mechanisms by
which synonymous mutations influence oncogene activity,
although they may still be important in individual cases (Gartner
et al., 2013).
Synonymous Mutations in Oncogenes Target Exonic
Splicing Motifs
An additional step in gene expression influenced by synonymous
mutations is pre-mRNA splicing, with coding exons containing
both exonic splicing enhancer (ESE) and exonic splicing silencer(ESS) motifs that are under evolutionary constraint (Keren et al.,
2010; Parmley et al., 2006) and with variants in these exonic mo-
tifs leading to altered splicing (Cartegni et al., 2002). Mutations in
intronic splicing donor or acceptor sites are a common mecha-
nism of tumor suppressor gene inactivation, and changes in
splicing can also deregulate the activity of oncogenes (Druillen-
nec et al., 2012; Kaida et al., 2012). Changes in splicing were
also recently identified as a mechanism of acquired drug resis-
tance in the BRAF (Poulikakos et al., 2011) and AR (Li et al.,
2012) genes, where the underlying causes were either unknown
(for BRAF) or intragenic deletions (AR).
Consistent with a role in splicing, synonymousmutations in the
16-oncogene set are 1.753 enriched within 30 nt of an exon
boundary in oncogenes (Figure 4A; p < 104), but not in tumor
suppressor genes (Figure 4A). Moreover, using the results of a
study that tested all possible hexamers for ESE or ESS activity
(Ke et al., 2011) revealed that cancer-associated synonymous
mutations close to exon boundaries preferentially result in the
gain of ESE motifs and the loss of ESS motifs (Figure 4B). This
is not the case for synonymous mutations in tumor suppressor
genes (Figure 4B). The same trends are seen when considering
motifs identified by screening a random oligonucleotide library
for ESS activity using an in vivo splicing reporter system (Wang
et al., 2004) (Figure 4C). The ESE motifs identified through a sta-
tistical analysis of exon composition (Fairbrother et al., 2002)
also predict that cancer-associated synonymous mutations
tend to create ESEs in oncogenes (Figure 4D), but not in
tumor suppressors. Across the three definitions of ESE/ESS,Cell 156, 1324–1335, March 13, 2014 ª2014 Elsevier Inc. 1329
Figure 5. Synonymous Mutations in Oncogenes Are Associated with Changes in Exon Usage Profiles in RNA-Seq Data
(A) Frequency of cancer samples harboring a synonymous mutation in an oncogene with strongly outlying exon abundance profiles, when compared against
other samples in a given tissue. p values by binomial test, where expected frequency is the average of lowest five bins.
(B) Estimated proportions of putative driver mutations among all synonymousmutations and of splicing-affecting drivers among all synonymous drivers, the latter
corresponding to the excess of outlying exon usage profiles over the expectation. The ‘‘other putative drivers’’ encompass the excess of synonymous mutations
in the oncogenes that did not provoke splicing changes and thus likely act via a different mechanism. The ‘‘putative passengers’’ represent the baseline frequency
of synonymous mutations. In all panels, examined oncogenes are the 16 genes with >1.53 overall synonymous enrichment (Figures 3A and 3B), plus ALK and
NOTCH2, which are individually significant.
(C) Cumulative histograms of the outlier measure for the samples where the 18 oncogenes harbor a synonymous or nonsynonymousmutation or are not mutated.
Matched non-cancer genes given for comparison. p values for difference of distributions by K-S test.
(D) As above but for rank-normalized median RPKM of all exons of a transcript.
(E) The outlier measure visualized for oncogenes in samples where they harbor a synonymous mutation. FDR by c2 test on squared Mahalanobis distance.comparing the synonymous against the missense mutations in
the same genes as a baseline gives a similar result: the synony-
mous mutations tend to lead to ESE gains and ESS losses more
often than the missense mutations (Figures 4B–4D). Moreover,
randomizing the positions of the synonymousmutations strongly
reduces or abolishes the enrichments (Figures 4B–4D), meaning
that the enrichment cannot be explained by an increased density
of ESE/ESS elements in the oncogenes. ESE and ESSs tend to
play more important roles in exon definition when the flanking
splice sites are weaker, i.e., more divergent from the consensus
splice site sequences (Fairbrother et al., 2002). Consistent with
this, we found that exons of the 16-oncogene set that harbor
more synonymous mutations tend to have weaker splice sites
(Figure 4E; p = 0.019).
Clustering the sequences in the close vicinity of the ESE/ESS-
altering synonymous mutations (±5 nt, because ESE/ESS are
hexamers), we found one dominant cluster that encompasses
43%of examined ESE gain events (Figure 4F) and two large clus-
ters for the ESS losses, encompassing 22% and 20% of ESS
losses (Figure 4G). The consensus sequence of the ESE cluster
is compatible with the known binding site of the SRSF1 (SF2/
ASF) splicing factor (Figure 4F), which can act as a potent onco-
protein (Karni et al., 2007). Moreover, a cluster of ESS loss
sequences closelymatches the known binding site of the hetero-
geneous nuclear ribonucleoprotein (hnRNP) H2 splicing factor
(Figure 4G). Previously, hnRNP H2-mediated regulation has
been implicated in anticancer drug resistance (Stark et al.,
2011). It is thus conceivable that gain of binding of SF2/ASF1330 Cell 156, 1324–1335, March 13, 2014 ª2014 Elsevier Inc.and loss of binding of hnRNPs contributes to splicing regulation
with consequences for tumor progression.
Synonymous Mutations in Oncogenes Are Associated
with Abnormal Splicing
We examined >2,000 cancer exomes that had matching RNA
sequencing (RNA-seq) measurements, searching for splicing
irregularities associated with synonymous mutations by employ-
ing a multivariate outlier measure, the Mahalanobis distance
(De Maesschalck et al., 2000; Mahalanobis, 1936). This method
accounts for the correlation structure between variables (exon
levels), as well as for the variability of each variable, and can
be understood as a multivariate generalization of a Z score.
This revealed a strong association between synonymous muta-
tions and differential exon usage profiles in the most recurrently
mutated oncogenes (p = 0.0004; Figures 5A and 5C). This is not
the case for samples harboring nonsynonymousmutations in the
same genes (Figure 5C) or for the splicing of non-cancer genes
with synonymous mutations (Figure 5C). The oncogenes exhibit
no significant change in their overall expression level in the sam-
ples with synonymous mutations (Figure 5D). Importantly, the
strongest deviations in the splicing patterns (top 10% by outlier
score; rightmost bar in Figure 5A) are the ones most enriched in
the synonymous-mutated oncogenes (p = 2 3 106), with some
enrichment also noted for moderate changes in splicing patterns
(top 30%; Figure 5A; p = 0.002).
Across tumor types, the frequency of aberrant splicing profiles
detectable in the RNA-seq data allowed us to conservatively
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Figure 6. Effects of Cancer-Associated
Synonymous Mutations in Oncogenes and
TP53 in an In Vivo Splicing Assay
(A–D) Losses or gains of ESE/ESS motifs in JAK3,
NTRK1, and ITK oncogenes alter exon inclusion
levels. For each genotype, triplicate transfections
are shown. Average ± SD% exon skipping shown.
*Uppermost bands in (B) result from an activation
of a downstream cryptic splice site in the reporter
gene intron (62 nt away). The slightly shifted in-
clusion band inmutant ITK exon 13 (C) is not due to
aberrant splicing.
(E) TP53 is highly enriched with synonymous
mutations adjacent to splice sites. Error bars are
95% CI.
(F and G). Two sites at the 30 ends of TP53 exons 4
and 6 harbor recurrent synonymous (F) and
missense mutations (G).
(H) The synonymous mutation at the 30 end of exon
6 activates a cryptic splice site, resulting in a
frameshifted mRNA.
See also Figure S5.estimate that approximately half of the putative synonymous
drivers are associated with splicing changes (Figure 5B). More-
over, we note that splicing alterations may be more frequent
for some oncogenes (e.g., ITK, ALK, IDH1, or BCL6) than for
others (Figure 5E), although other oncogenes (including EGFR,
KDR, and PDGFRA) also contain multiple instances of synony-
mous mutations in samples with significantly outlying exon
usage profiles (Figure 5E).
Cancer-Associated Synonymous Mutations Alter
Splicing in Minigene Assays
To further validate our findings, we experimentally evaluated
the effects of 12 synonymous mutations in five oncogenes
(Extended Experimental Procedures) by examining changes in
splicing patterns induced by the mutations using minigenes
transfected in HeLa cells. Briefly, for each mutation tested,
exonic and flanking intronic sequences of wild-type and mutantCell 156, 1324–1335were cloned to replace an alternative
cassette exon in a reporter plasmid
(Orengo et al., 2006) and the patterns of
exon inclusion/skipping of transcripts
derived from the minigene were analyzed
(see Experimental Procedures). The
examined oncogene exons were selected
such that the wild-type minigene ex-
hibited measurable levels of both exon
inclusion and skipping in this experi-
mental setup. In total, six of the mutations
affected alternative splicing: two muta-
tions in exon 15 of JAK3, one mutation
in exon 14 of NTRK1, and two mutations
in exon 4 and one in exon 13 of ITK. In
all cases, the mutations are located in
the tyrosine kinase domains of the corre-
sponding proteins, except for ITK exon 4,
which overlaps a pleckstrin homologydomain. The two mutations in JAK3 exon 15 affect neighboring
codons and were predicted to lead to ESS losses in two overlap-
ping ESS hexamers (Figure 6A); they induced a clear reduction
(14%–23%) in exon-skipping frequency in the splicing assay
(Figure 6A). Similarly, theNTRK1mutation resulted in a reduction
in exon skipping (Figure 6B, 23%), consistent with its predic-
tion as an ESE gain event; we also observed an increased abun-
dance of an aberrantly spliced product (asterisk in Figure 6B).
Finally, in the ITK oncogene, the two mutations in exon 4 were
predicted to result in ESS losses (Figure 6D). Both mutations
decreased the skipping/inclusion ratio and, moreover, increased
the overall levels of mRNA (Figure 6D). A third mutation in ITK
was predicted to cause both ESE gain and ESE loss events
in overlapping motifs in exon 13 and led to an increase in exon
skipping (10%; Figure 6C).
In all cases except ITK exon 4, exon skipping is predicted to
result in a frameshift, suggesting that increased inclusion might, March 13, 2014 ª2014 Elsevier Inc. 1331
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Figure 7. Dosage-Sensitive Oncogenes Are
Enriched with 30 UTR Mutations
(A) Enrichments of cancer genes with synony-
mous, 30 UTR, and intronic mutations. Error bars
are 95% CI. FDR shown for 30 UTR enrichment.
(B) Complementary definitions of dosage-sensitive
cancer genes through their overexpression across
many cancers or by orthology to genes from
mouse mutagenesis screens. GXA, Gene Expres-
sion Atlas.
(C) Enrichment of individual dosage-sensitive
genes with 30 UTR mutations; oncogenes from the
amplified and mouse sets are shown. Error bars
are 95% CI. Significance calls by Z-test of the log
enrichment (one tailed).
(D) Clustering of mutations in the 30 UTRs of
dosage-sensitive oncogenes. p values by Fisher’s
exact test (one tailed).
See also Figure S5 and Table S7.lead to increased expression of the full-length isoform and
consequently higher oncogene activity. Taken together, the
detection of splicing changes in 6 out of 12 (50%; 95% CI:
21%–79%) of the tested cases is consistent with the estimate
derived from the RNA-seq data that approximately half of synon-
ymous drivers in oncogenes have effects on alternative splicing.
Recurrent Synonymous Mutations in TP53 Inactivate
Splice Sites
Although, considered together, tumor suppressors did not show
an enrichment of synonymous mutations, when considered
individually, one tumor suppressor, TP53, was strongly enriched
(Figure 6E; 3.993). The TP53-synonymous mutations were also
extremely recurrent and, in contrast to those in oncogenes,
target nucleotides directly adjacent to splice sites (75% of the
synonymous mutations recur in three such nucleotides). Indeed,
upon masking the terminal 2 nt of its exons, TP53 shows no syn-
onymousmutation enrichment (Figure 6E), consistent with previ-
ous estimates that most synonymous mutations in TP53 are
neutral (Strauss, 2000). However, an enrichment in evolutionarily
conserved sites suggests a functional role for a subset of muta-
tions (Lamolle et al., 2006).
Recurrently targeted synonymous sites in TP53 include the 30
terminal nucleotide of TP53 exon 4 (in codon 125; Figure 6F).
Strikingly, a germline variant at the same site is a known cause
of Li-Fraumeni syndrome, producing an aberrantly spliced
TP53 mRNA that causes intron retention (Warneford et al.,
1992) and activation of cryptic splice sites (Varley et al., 1998).
In addition, the 30 terminal nucleotide of exon 6 is also recurrently
mutated (codon 224; Figure 6G) with both synonymous and con-
servative missense changes (Glu > Asp). We confirmed using an
in vivo splicing assay that this mutation results in aberrant
splicing, activating a cryptic splice site 5 nt downstream from
the end of exon 6 and resulting in a frameshifted mRNA (Fig-
ure 6H). The wild-type splice site at the 50 of TP53 exon 6 has
only a limited match to the consensus (AG/gtctgg versus AG/
gtaagt); the exonic G > A change further weakens it, being the1332 Cell 156, 1324–1335, March 13, 2014 ª2014 Elsevier Inc.likely cause for the use of the downstream cryptic splice site
that has a G as the 30 nucleotide of the extended exon 6. More-
over, we found a third recurrently mutated site in TP53 with
similar properties, where the 30 terminal G of exon 9 is commonly
lost (codon 331; Figure S5). Thus, at least one tumor suppressor
gene is also targeted by recurrent synonymous mutations at
multiple locations, but, in contrast to those in oncogenes, these
mutations inactivate splice sites.
Dosage-Sensitive Oncogenes Have an Excess of
Mutations in Their 30 UTRs
Finally, we reasoned that our analytical approach might also be
useful for identifying additional classes of recurrent mutations
in cancer genomes. We focused on mutations in untranslated
regions because, similar to synonymous mutations, these have
not been extensively investigated and are known to be important
for regulating gene expression. In contrast to the situation with
synonymous mutations, missense-activated oncogenes and
the recurrently mutated oncogenes showed no enrichment
for mutations in their 30 UTRs (Figure 7A). However, one set of
oncogenes did show a clear enrichment of mutations in 30
UTRs: those oncogenes that can be activated by amplification
(1.193, p = 0.03; Figure 7A).
We hypothesized, therefore, that other dosage-sensitive on-
cogenes—those activated by elevated expression—might also
show an enrichment of somatic mutations in their 30 UTRs.
Consistent with this, we found that cancer genes that are consis-
tently overexpressed in human tumors (Figure 7B) and the ortho-
logs of dosage-sensitive oncogenes identified in mice using
transposon and retroviral screens (Figure 7B) both also showed
an elevated rate of mutation in their 30 UTRs (1.263 and 1.403,
p = 0.002 and 0.004; Figure 7A). None of the three groups of
dosage-sensitive oncogenes exhibited an excess of synony-
mous or intronic mutations (Figure 7A), demonstrating that
regional mutation rate variations do not underlie the enrich-
ments. When considering the opposite definitions of the
above—cancer genes consistently underexpressed in human
tumors or the orthologs of tumor suppressors found in mouse
screens—neither group showed any 30 UTR mutation enrich-
ment (Figure 7A). Moreover, 17 of the dosage-sensitive onco-
genes wereR23 enriched with 30 UTR mutations, of which ten
genes were individually significant at FDR % 10% (Figure 7C).
Within the highly enriched dosage-sensitive oncogenes, the 30
UTR mutations clustered (Figure 7D), and we provide the muta-
tion clusters in the significantly enriched genes as a resource
(Figure S5; Table S7). Thus, our method was able to identify
another unexpected enrichment of mutations in cancer ge-
nomes, predicting that dosage-sensitive oncogenes may be
recurrently activated by mutations in their 30 UTRs.
DISCUSSION
The large-scale sequencing of cancer genomes provides an op-
portunity to reassess the types of mutations that contribute to
cancer in an unbiased manner. From their excess in oncogenes
(see Extended Experimental Procedures), we estimate that
approximately one in five synonymous mutations in all known
oncogenes reported to-date in cancer genome projects have
been selected, with this proportion rising to approximately one
in two for the oncogenes most relevant to each cancer type.
From the frequency at which synonymous changes occur
compared to nonsynonymous mutations within oncogenes
(see Extended Experimental Procedures), synonymous muta-
tions represent 6%–8% of all driver mutations due to single-
nucleotide changes in these genes. Therefore, as part of their
standard analyses, future cancer genome studies should test
for enrichment and recurrence of synonymous changes.
Moreover, our combined computational and experimental an-
alyses estimated that approximately half of synonymous drivers
alter splicing. In future experimental work, it will be important to
further dissect how these changes in splicing influence cancer
progression and how they can be therapeutically targeted (Bon-
nal et al., 2012). In addition to their effects on splicing, it is known
that synonymous mutations can alter protein folding (Kimchi-
Sarfaty et al., 2007; Zhang et al., 2009; Zhou et al., 2013), and
our preliminary analyses suggest that this might also be relevant
in cancer (Figure S4).
As illustrated by our discovery of selected mutations in the 30
UTRs of dosage-sensitive oncogenes, the general approach
presented here may be useful for identifying additional classes
of unexpected cancer driver mutations and thus provide a fuller
understanding of how changes in cancer genomes contribute to
tumor progression in individual patients.
EXPERIMENTAL PROCEDURES
For a more exhaustive description of the computational analyses, as well as
the minigene splicing experiments, please refer to Extended Experimental
Procedures.
Genomic Data, Cancer Genes, and Matched Sets
Somatic mutations in 3,851 cancer exomes were from the Cancer Genome
Atlas (TCGA) Data Portal (Zhang et al., 2011) and from the exome sequencing
studies in COSMIC v61 (Forbes et al., 2011) that reported synonymous muta-
tions (Table S2). Somatic mutations in 167 cancer genomes from the Interna-
tional Cancer Genome Consortium Data Portal v8 and additional publications(Table S2) were used to determine 1Mb/200 kb regional mutation rates. Of 219
additional whole genomes from the TCGA project (Table S2), mutations in 50
leukemias were from Cancer Genome Atlas Research Network (2013),
whereas for others, including the 24 glioblastomas (Brennan et al., 2013),
aligned short reads were downloaded from cgHub and somatic mutations
called using Strelka 1.0.6 (Saunders et al., 2012). cDNAs from COSMIC v61
were matched to transcript models from RefSeq or Ensembl in the University
of California, Santa Cruz (UCSC) ‘‘golden path’’ repository. Nonunique
genomic regions in the ‘‘CRG Alignability 36’’ UCSC track were masked out
and sequencing error-prone motifs checked for (Figure S6). The regional mu-
tation rates for different cancers (Figure 1B), gene mRNA levels in ten tissues
(Figure S7), and GC3 content in cDNA, together with H3K9me3 (CD4+ cells)
and Repli-Seq (NHEK cells, wgEncodeEH002249) signal averaged over
1 Mb windows, was used to find matched sets using a genetic algorithm
(GA)-based optimization. The GA minimizes the cDNA length-weighted Kol-
mogorov-Smirnov distance of the distributions of mutation rates and other
genomic features to the cancer gene set in question by iteratively ‘‘recombin-
ing’’ and ‘‘mutating’’ the matched-set candidates. Matched sets for single
cancer genes were constructed from 200 genes closest by Euclidian distance
using trimmed and normalized mutation rates, mRNA levels, etc. Mutation
enrichment is calculated as a relative risk of mutation compared to the
matched set and significance determined by a Z-test on the standard error
of the log RR. The tissue-specific oncogenes/tumor suppressors are those
individually significantly enriched with either missense or nonsense mutations
in a specific tissue (median FDR across tissues = 7.3%; list in Table S4).
Analyses of Splicing Motifs and Data
Complete sets of 176 ESSs from Wang et al. (2004) and 238 ESEs from Fair-
brother et al. (2002), as well as the top 200 ESEs and ESSs from Ke et al.
(2011), were tested for enrichments (using c2 tests) of gain versus loss events
caused by synonymous mutations in oncogenes, compared to the matched
sets, missense mutations, or randomized positions. Splice-site strength was
determined as the average log likelihood of the nucleotides in the splice site,
given the consensus position weight matrixes (PWMs) in SpliceRack (Sheth
et al., 2006). Motifs around the ESE/ESS-altering synonymous mutations
were discovered in the mutated site and its ±5 nt context by the MEME
4.9.0 server (Bailey et al., 2009) with motif size = 6–8 and other parameters
at default. Sequences in the large ESE gain cluster were submitted to
ESEFinder 3.0 (Smith et al., 2006), which classifies whether each sequence
will bind a splicing factor based on an empirical threshold. We searched the
PWM of a major ESS loss cluster against CISBP-RNA 0.6 (Ray et al., 2013)
to find human RNA-binding proteins with significantly similar binding sites.
The shown SF2/ASF motif is from Smith et al. (2006) and the hnRNP H2 motif
is from Ray et al. (2013). Available data from the TCGA ‘‘RNASeqV2’’ pipeline
(October 2013) were matched to existing TCGA samples with exonic muta-
tions. Genes not expressed (if third quartile across exons [Q3], <1.0 reads
per kilobase per million [RPKM]) were not examined further in corresponding
samples; genes grossly overexpressed compared to other samples of same
tissue (if Q3 an outlier according to 1.5 3 IQR rule) were also discarded. The
square root was used as a variance-stabilizing transformation for RPKMs prior
to calculating the Mahalanobis distances, which were converted to ranks and
normalized to [0,1] separately for each gene in each tissue, before pooling.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and seven tables and can be found with this article online at http://dx.
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